What the Company Does

RTC's core business is to conduct non-clinical (pre-clinical) safety evaluations for a wide range of products before they can proceed to human clinical trials or market authorization. This involves assessing the potential toxicity and safety profile of new chemical entities, pharmaceutical drugs, medical devices, agrochemicals, food additives, cosmetics, and other health-related products. Their work is crucial in ensuring that products are safe for human use and the environment, thereby supporting global regulatory submissions (e.g., FDA, OECD, ICH, EMA).

The company operates with a strong scientific foundation and a commitment to regulatory compliance. Their integrated approach allows them to support clients from the very early stages of product development through to final registration. Key aspects of RTC's operations include:

• Regulatory Compliance: All studies are performed in strict accordance with international guidelines and regulations, including GLP (Good Laboratory Practice), which ensures the quality and integrity of non-clinical safety data. RTC facilities are regularly audited by regulatory bodies, demonstrating their commitment to compliance.
• Scientific Expertise: RTC employs a multidisciplinary team of highly experienced toxicologists, pathologists, pharmacologists, chemists, and other scientific personnel. This expertise allows them to design, execute, and interpret complex toxicology studies.
• Customized Study Design: They offer tailored approaches to preclinical development, designing study protocols that meet specific client requirements and the unique characteristics of the test compounds or products.
• Advanced Facilities: RTC operates state-of-the-art animal facilities (AAALAC accredited) and laboratories equipped with modern instrumentation for various analyses, including clinical pathology, histopathology, and bioanalytical studies.
• Ethical Practices: The company is committed to ethical animal welfare, adhering to the 3Rs principles (Replacement, Reduction, Refinement) where possible, and employing validated and ethical animal models for predictive insights.
• Data Integrity and Reporting: RTC emphasizes robust data integrity management and provides comprehensive scientific and regulatory dossier documents, including IUCLID files, Robust Summaries, CSA/CSR, and technical dossiers. They also provide expert interpretation of study findings.

RTC's role is critical in mitigating risks associated with new product development, ensuring that only safe and thoroughly tested substances reach the market.

Products and Services

As a Contract Research Organization, RTC does not produce tangible "products" in the consumer sense. Instead, its "products" are the high-quality data, comprehensive reports, and expert scientific opinions derived from their specialized studies. Their offerings are primarily a range of non-clinical research and consultancy services.

Services Offered:

1. General Toxicology Studies:

   • Acute Toxicity Studies: Single-dose studies to determine the immediate toxic effects of a substance (e.g., acute oral, dermal, inhalation toxicity).
   • Repeat-Dose Toxicity Studies: Studies involving repeated administration of a substance over various durations (e.g., 4-day, 7-day, 14-day, 28-day, 90-day, subchronic, chronic toxicity studies up to 1 year or more). These studies aim to identify target organs, dose-response relationships, and the No-Observed-Adverse-Effect-Level (NOAEL).
   • Dose Range Finding (DRF) Studies: Exploratory studies to determine appropriate dose levels for definitive toxicology studies.
   • Maximum Tolerated Dose (MTD) Determination: Identifying the highest dose of a substance that can be given without causing unacceptable adverse effects.
   • Toxicokinetic (TK) Studies: Studies that investigate the Absorption, Distribution, Metabolism, and Excretion (ADME) of a substance, often integrated as satellite groups within toxicology studies.

2. Genetic Toxicology Studies (Genotoxicity): Assessing the potential of a substance to damage genetic material (DNA), which could lead to mutations or cancer.

   • In vitro Genotoxicity Testing:
     • Bacterial Reverse Mutation Assay (Ames Test - OECD 471)
     • In vitro Mammalian Chromosomal Aberration Test (OECD 473)
     • In vitro Mammalian Cell Micronucleus Test (OECD 487)
   • In vivo Genotoxicity Testing:
     • Mammalian Erythrocyte Micronucleus Test (OECD 474)
     • In vivo Mammalian Alkaline Comet Assay (OECD 489)
     • Mammalian Bone Marrow Chromosomal Aberration Test (OECD 475)

3. Safety Pharmacology Studies: Evaluating the potential effects of a substance on vital physiological functions (e.g., cardiovascular, central nervous, respiratory systems) that are not directly related to its intended therapeutic effect. These studies are critical for identifying potential adverse effects on major organ systems.

4. Reproductive and Developmental Toxicity (DART) Studies: Assessing the potential effects of a substance on fertility, reproductive performance, and embryonic/fetal development.

   • Fertility and Early Embryonic Development Studies
   • Embryo-Fetal Development Studies
   • Pre- and Post-natal Development Studies
   • Juvenile Toxicity Studies

5. Carcinogenicity Studies: Long-term studies (typically 2 years in rodents) to determine if a substance has the potential to cause cancer.

6. Pathology Services:

   • Gross Pathology: Macroscopic examination of organs and tissues at necropsy.
   • Histopathology: Microscopic examination of tissue samples from various organs, providing detailed insights into cellular and tissue changes. This includes advanced staining techniques (IHC, IF, ISH).
   • Clinical Pathology: Analysis of blood (hematology, clinical chemistry) and urine samples to detect systemic toxicity.
   • Digital Pathology and Telepathology: Utilizing advanced imaging and remote consultation tools (e.g., Augmentiqs) for efficient collaboration and expert review of histopathological slides.

7. Bioanalytical Services: Supporting toxicology studies by analyzing drug concentrations in biological samples (e.g., plasma, tissues) to determine exposure levels and toxicokinetics.

8. Consultancy Services:

   • Project Design: Assisting clients in designing comprehensive toxicology testing programs tailored to specific regulatory requirements and product types.
   • Regulatory Strategy: Providing guidance on regulatory requirements, data gap analysis, read-across, QSAR/SAR evaluation, waiving strategies, and direct liaison with regulatory authorities.
   • Dossier Preparation: Assisting in the preparation of scientific and regulatory documents such as IUCLID 6 files, Robust Summaries, Chemical Safety Assessments (CSA)/Chemical Safety Reports (CSR), and Technical Dossiers for various regulations (e.g., REACH, Biocidal Products Regulation, Food and Feed legislation).
   • Risk Assessment: Evaluating exposure scenarios and conducting risk assessments to determine the overall safety of a product.
   • Hazard Classification and Labeling: Providing proposals for hazard classification and labeling in accordance with GLP.

RTC's extensive portfolio of services makes it a crucial partner for industries worldwide in navigating the complex landscape of product safety and regulatory compliance.